2489185-38-6
Chemical Structure
Enozertinib
Synonym(s): ORIC-114
- CAS No.: 2489185-38-6
- Formula:C35H42F2N8O3
- Molecular Weight:660.76
InChIKey: NNDXFTMFJKUUQA-SSEXGKCCSA-N
SMILES: C=CC(NC1=C(N2CCC(N3CCN(C4CC4)CC3)CC2)C=C(C(NC5=NC=NC(N6[C@@H](C7=CC(F)=CC(F)=C7)CCO6)=C5)=C1)OC)=O
Biological Activity: Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enozertinib | 98.86% | Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. M.H. Hong, et al. 1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations. Annals of Oncology, Volume 34, S769.
- [2]. Jason E. Long, et al. ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3335.
Keywords
